A Global Approach To Medtech Regulation: The Post-EU Way Ahead For UK Industry?
As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.
You may also be interested in...
The Medicines and Medical Devices Act presses the UK to regulate in such a way that makes the market attractive for industry and investment. Medtech manufacturers insist the MHRA must strike the right balance as it brings its ‘plan for a new agency’ to life, said the ABHI’s Phil Brown, in the second of a two-part industry view of UK medtech’s regulatory future.
ABHI’s Phil Brown looks beyond the immediate challenges for UK medtechs on being outside the EU, and to an innovation-friendly, patient-responsive system of future regulation.
Parliamentary committee meetings on the UK’s devices bill have been postponed as measures to tackle COVID-19 have been moved to center stage.